Keros Therapeutics, Inc. (KROS)
10.27
-0.23
(-2.19%)
USD |
NASDAQ |
May 18, 13:19
Keros Therapeutics Research and Development Expense (Quarterly) : 16.10M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Sarepta Therapeutics, Inc. | 153.96M |
| PTC Therapeutics, Inc. | 100.87M |
| Insmed, Inc. | 209.48M |
| United Therapeutics Corp. | 138.20M |
| Enanta Pharmaceuticals, Inc. | 19.44M |